Devika Gajria

1.2k total citations
31 papers, 867 citations indexed

About

Devika Gajria is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Devika Gajria has authored 31 papers receiving a total of 867 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Devika Gajria's work include HER2/EGFR in Cancer Research (15 papers), Cancer Treatment and Pharmacology (14 papers) and Advanced Breast Cancer Therapies (7 papers). Devika Gajria is often cited by papers focused on HER2/EGFR in Cancer Research (15 papers), Cancer Treatment and Pharmacology (14 papers) and Advanced Breast Cancer Therapies (7 papers). Devika Gajria collaborates with scholars based in United States, United Kingdom and Palestinian Territory. Devika Gajria's co-authors include Sarat Chandarlapaty, Shanu Modi, Shari Goldfarb, Mario E. Lacouture, Clifford A. Hudis, Donald Chan, Larry Norton, Azael Freites‐Martínez, Monica Fornier and Jerry Shapiro and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Devika Gajria

31 papers receiving 856 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Devika Gajria United States	12	536	322	190	136	123	31	867
Amy Freyman United States	7	418 0.8×	263 0.8×	97 0.5×	326 2.4×	34 0.3×	12	657
Sherry Yang United States	10	305 0.6×	210 0.7×	65 0.3×	60 0.4×	115 0.9×	32	645
Mareyuki Endoh Japan	18	187 0.3×	306 1.0×	73 0.4×	195 1.4×	158 1.3×	33	786
Amarnath Challapalli United Kingdom	15	171 0.3×	170 0.5×	368 1.9×	258 1.9×	221 1.8×	59	816
Michael E. Menefee United States	15	610 1.1×	484 1.5×	49 0.3×	209 1.5×	181 1.5×	45	1.3k
Pooja Ghatalia United States	20	517 1.0×	633 2.0×	45 0.2×	653 4.8×	330 2.7×	81	1.4k
Mary Robinson United Kingdom	17	280 0.5×	336 1.0×	52 0.3×	424 3.1×	253 2.1×	30	961
R. Mione Italy	14	282 0.5×	280 0.9×	150 0.8×	118 0.9×	143 1.2×	46	629
Andrea Milani Italy	12	416 0.8×	268 0.8×	81 0.4×	208 1.5×	123 1.0×	35	765
Abdel‐Aziz A. Elgamal United States	17	242 0.5×	401 1.2×	199 1.0×	902 6.6×	310 2.5×	24	1.4k

Countries citing papers authored by Devika Gajria

Since Specialization

Citations

This map shows the geographic impact of Devika Gajria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devika Gajria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devika Gajria more than expected).

Fields of papers citing papers by Devika Gajria

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devika Gajria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devika Gajria. The network helps show where Devika Gajria may publish in the future.

Co-authorship network of co-authors of Devika Gajria

This figure shows the co-authorship network connecting the top 25 collaborators of Devika Gajria. A scholar is included among the top collaborators of Devika Gajria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Devika Gajria. Devika Gajria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reingold, Rachel, Alexander Pan, Lukas Kraehenbuehl, et al.. (2024). Oral minoxidil for late alopecia in cancer survivors. Breast Cancer Research and Treatment. 208(3). 491–499. 8 indexed citations

Lacouture, Mario E., Alexander Pan, Anna Chen, et al.. (2024). Abstract 3412: Benralizumab for treatment of eosinophil-related cutaneous adverse events associated with checkpoint inhibitors and anticancer targeted therapies: Phase 2 study. Cancer Research. 84(6_Supplement). 3412–3412. 1 indexed citations

Lacouture, Mario E., Alexander Pan, George Dranitsaris, et al.. (2022). Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer.. Journal of Clinical Oncology. 40(16_suppl). 12100–12100. 2 indexed citations

Chan, Donald, et al.. (2019). CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients.. Journal of Clinical Oncology. 37(15_suppl). e12537–e12537. 7 indexed citations

Cadoo, Karen A., Devika Gajria, Sujata Patil, et al.. (2016). Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review. npj Breast Cancer. 2(1). 16006–16006. 8 indexed citations

Iyengar, Neil M., Monica Fornier, Steven Sugarman, et al.. (2015). A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer. 16(2). 87–94. 2 indexed citations

Gajria, Devika, Shanu Modi, Cristina Saura, et al.. (2015). Abstract P5-19-04: A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy. Cancer Research. 75(9_Supplement). P5–19. 5 indexed citations

Dang, Chau T., Neil M. Iyengar, Gabriella D’Andrea, et al.. (2014). Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 33(5). 442–447. 55 indexed citations

Iyengar, Neil M., Monica Fornier, Steven Sugarman, et al.. (2014). Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC).. Journal of Clinical Oncology. 32(15_suppl). 633–633. 1 indexed citations

10.

D’Andrea, Gabriella, Shari Goldfarb, Maria Theodoulou, et al.. (2013). Abstract P2-16-07: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data. Cancer Research. 73(24_Supplement). P2–16. 2 indexed citations

11.

Hudis, Clifford A., Charles Swanton, Yelena Y. Janjigian, et al.. (2013). A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Research. 15(6). R110–R110. 85 indexed citations

12.

D’Andrea, Gabriella, Maura N. Dickler, Maria Theodoulou, et al.. (2012). Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).. Journal of Clinical Oncology. 30(27_suppl). 134–134. 5 indexed citations

13.

Gajria, Devika, Kimberly Feigin, Lee K. Tan, et al.. (2011). Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer. 117(18). 4125–4131. 15 indexed citations

14.

Larson, Sarah M., Nicholas Campbell, Dezheng Huo, et al.. (2011). High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML). Leukemia & lymphoma. 53(3). 445–450. 21 indexed citations

15.

Gajria, Devika, Kimberly Feigin, Sujata Patil, et al.. (2011). Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 131(1). 111–116. 19 indexed citations

16.

Gajria, Devika & Sarat Chandarlapaty. (2011). HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy. 11(2). 263–275. 369 indexed citations

17.

Gajria, Devika, Tari A. King, Harpreet K. Pannu, et al.. (2011). PD09-08: Combined Inhibition of mTORC1 with Temsirolimus and HER2 with Neratinib: A Phase I/II Study in Patients with Metastatic HER2−Amplified or Triple-Negative Breast Cancer.. Cancer Research. 71(24_Supplement). PD09–8. 14 indexed citations

18.

Gajria, Devika, Andrew D. Seidman, & Chau T. Dang. (2010). Adjuvant Taxanes: More to the Story. Clinical Breast Cancer. 10. S41–S49. 11 indexed citations

19.

Larson, Sarah M., Nicholas Campbell, Dezheng Huo, et al.. (2009). High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).. Blood. 114(22). 1048–1048. 2 indexed citations

20.

Odenike, Olatoyosi, Richard A. Larson, Devika Gajria, et al.. (2008). Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Investigational New Drugs. 26(3). 233–239. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact